Mobidiag Announces Agency Agreement with YouMed for the Commercialization of its Molecular Diagnostic Product line Amplidiag® in UK
Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with YouMed Ltd, bespoke sales, marketing and distribution of high-quality medical technologies, regarding the Amplidiag® product line. Under this agreement YouMed becomes an agent for commercialization in UK of Amplidiag® product line, in vitro diagnostic tests and compatible system for the detection of gastrointestinal infections.
“For the past months, we have been extending significantly our European distribution network. Making our Amplidiag product line available in UK was definitely our next strategic step. Besides being clearly a high-value market, I strongly believe that our Amplidiag suite can bring great benefits to UK’s healthcare professionals. With that in mind, we are happy to initiate our partnership with YouMed as our local agent to expand Mobidiag’s market reach and visibility in UK” said Tuomas Tenkanen, CEO at Mobidiag.
“YouMed are proud and excited to be partnering with Mobidiag bringing their Amplidiag range of products to the UK healthcare market. There is an unmet need in the UK molecular diagnostic market for accurate, reliable testing for Gastro-intestinal pathogens. We are confident the Mobidiag assays and systems can have a positive impact on management of patients suffering from these infections” said Christopher Brain, Managing Director at YouMed Ltd.
The agreement is effective immediately and covers all Amplidiag® IVD tests (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE and upcoming Amplidiag® Viral GE) as well as the upcoming Amplidiag® Easy system.
About Amplidiag® assays
Amplidiag® assays are innovative
multiplex tests for the detection of gastrointestinal infections. They
allow to screen panels of the most relevant gastrointestinal pathogens.
Based on well-established real-time PCR technology, they ensure optimal
performance, suitability for high-volume screening use and
cost-effectiveness in mid-sized to large laboratory settings.
About Mobidiag Ltd
Established in 2000, Mobidiag develops
innovative solutions to advance the diagnosis of infectious diseases and
serves the European clinical diagnostics market since 2008. Mobidiag is
headquartered in Espoo, Finland, with a subsidiary in Paris, France.
Mobidiag
addresses both high to medium volume screening with the new Amplidiag®
Easy platform, bringing the Amplidiag® suite further by automating the
workflow from sample to results, and the upcoming Novodiag® platform &
associated panels for a fully automated solution and suitable for
smaller volumes and labs.
Visit www.mobidiag.com
for more information.
About YouMed Ltd
YouMed is a privately owned company with
significant experience in selling products and services to primary and
secondary medical care sites throughout the UK and Ireland. YouMed
offers products and services across a defined range of clinical areas:
Diagnostics, Sports medicine, Orthopaedics and Consultancy. With wide
ranging experience in the delivery of point of care, oncology, genetics
and infectious disease products, YouMed ensures that high quality,
innovative technology is available in the laboratory for the benefit of
medical specialists and their patients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003005596/en/
Contact information
Mobidiag
Jan Wikstén, +46 707 75 11 67
jan.wiksten@mobidiag.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo